Format

Send to

Choose Destination
PLoS One. 2017 Aug 25;12(8):e0183448. doi: 10.1371/journal.pone.0183448. eCollection 2017.

Nipple sparing mastectomy in breast cancer patients and long-term survival outcomes: An analysis of the SEER database.

Li M1, Chen K2,3, Liu F2,3, Su F2,3, Li S2,3, Zhu L2,3,4.

Author information

1
Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian, China.
2
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
3
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
4
Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, Connecticut, United States of America.

Abstract

PURPOSE:

To determine the prevalence of nipple-sparing mastectomy (NSM) and its long-term survival outcomes in breast cancer patients.

METHOD:

We used the Surveillance, Epidemiology, and End Results database and identified 2,440 breast cancer patients who received NSM during 1998-2013. We used chi-square and binary logistic regression to identify factors associated with the use of radiotherapy after NSM. We used Kaplan-Meier analysis to estimate cancer-specific survival (CSS) and overall survival (OS). We used the log-rank test and Cox regression to identify factors associated with CSS and OS.

RESULTS:

The median age of the population was 50 years. There were 725 (29.7%), 1064 (43.6%) and 651 (26.7%) patients who had Tis, T1 and T2-3 disease and 1943 (79.6%), 401 (16.4%) and 96 (3.9%) patients who had N0, N1 and N2-3 disease, respectively. The rates of RT use were 61.4%, 39.6% and 10.9% in patients with N2-3 disease, N1 or T3/N0 disease and Tis/T1-2N0 disease, respectively. Elderly age, African American race, and higher T-stage and N-stage were associated with receiving radiotherapy. For patients diagnosed between 1998-2010 (N = 763), the median follow-up was 69 months. The 5- and 10-yr CSS were 96.9% and 94.9%, respectively. The 5- and 10-yr OS were 94.1% and 88.0%, respectively. Ethnicity, T-stage and N-stage were factors independently associated with CSS, and age and T-stage were factors independently associated with OS.

CONCLUSIONS:

The use of NSM has increased, and it is oncologically safe for breast cancer patients.

PMID:
28841691
PMCID:
PMC5571910
DOI:
10.1371/journal.pone.0183448
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center